Business Context and Reporting Period
This Form 6-K filing by China SXT Pharmaceuticals, Inc. covers the month of January 2022. The report primarily addresses a material change in executive leadership rather than financial performance.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current report on a corporate event and does not contain financial statements.
Material Changes
- Departure of CFO: Mr. Wang (Wallace) L. Lee resigned as Chief Financial Officer effective January 31, 2022. The resignation was not due to any disagreement with the Company regarding operations, policies, or practices.
- Appointment of New CFO: Mr. Xiaodong Pan was appointed as the new Chief Financial Officer effective immediately on January 31, 2022.
- New CFO Background: Mr. Pan has served as Finance Director of Jiangsu Suxuantang Pharmaceutical Co., Ltd. (the Company's consolidated variable interest entity) since March 2015. He holds a Bachelor's Degree in Accounting and a Master's Degree in Business Administration.
Guidance, Outlook, and Risks
The filing includes a standard special note regarding forward-looking statements. Management highlights several risks and uncertainties that could cause actual results to differ materially from expectations, including:
- The effects of the COVID-19 outbreak on product demand, operations, and market price.
- The duration and severity of the COVID-19 outbreak in operating regions.
- The pace of economic recovery and the ability to implement cost containment strategies.
- General economic conditions in China, government regulations, and competitive pricing pressures.
The Company explicitly states it undertakes no duty to update these forward-looking statements after the date of the report.
Investor Verification Checklist
- Verify the transition plan and handover status between the outgoing and incoming CFO.
- Review the attached employment agreement (Exhibit 10.1) for terms regarding Mr. Pan's compensation and tenure.
- Monitor subsequent filings for any financial impact related to the leadership change or ongoing COVID-19 disruptions.
- Confirm that no undisclosed disagreements existed regarding the resignation of the former CFO.